Campbell McInnes to Drug Design
This is a "connection" page, showing publications Campbell McInnes has written about Drug Design.
Connection Strength
2.877
-
Design and Synthesis of Type-IV Inhibitors of BRAF Kinase That Block Dimerization and Overcome Paradoxical MEK/ERK Activation. J Med Chem. 2019 04 25; 62(8):3886-3897.
Score: 0.632
-
The Meisenheimer Complex as a Paradigm in Drug Discovery: Reversible Covalent Inhibition through C67 of the ATP Binding Site of PLK1. Cell Chem Biol. 2018 09 20; 25(9):1107-1116.e4.
Score: 0.600
-
Improved lead-finding for kinase targets using high-throughput docking. Curr Opin Drug Discov Devel. 2006 May; 9(3):339-47.
Score: 0.258
-
Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle. IDrugs. 2006 Apr; 9(4):273-8.
Score: 0.256
-
PharmaDiscovery 2005. Kinases in drug discovery. IDrugs. 2005 Jul; 8(7):551-4.
Score: 0.243
-
Strategies for the design of potent and selective kinase inhibitors. Curr Pharm Des. 2005; 11(14):1845-63.
Score: 0.235
-
Inhibitors of the PLK1 polo-box domain: drug design strategies and therapeutic opportunities in cancer. Expert Opin Drug Discov. 2023 01; 18(1):65-81.
Score: 0.205
-
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors. J Vis Exp. 2015 Oct 26; (105):e52441.
Score: 0.124
-
PLK1 as an oncology target: current status and future potential. Drug Discov Today. 2011 Jul; 16(13-14):619-25.
Score: 0.091
-
REPLACE: a strategy for iterative design of cyclin-binding groove inhibitors. Chembiochem. 2006 Dec; 7(12):1909-15.
Score: 0.067
-
Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design. Chem Biol. 2006 Feb; 13(2):201-11.
Score: 0.063
-
Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors. Chem Biol. 2004 Apr; 11(4):525-34.
Score: 0.056
-
Calpain 10 homology modeling with CYGAK and increased lipophilicity leads to greater potency and efficacy in cells. ACS Chem Biol. 2012 Aug 17; 7(8):1410-9.
Score: 0.025
-
Truncation and optimisation of peptide inhibitors of cyclin-dependent kinase 2-cyclin a through structure-guided design. ChemMedChem. 2009 Jul; 4(7):1120-8.
Score: 0.020